Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGG1 | O15527 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27998198 | 0.81 | OGG1 (0.60) | OGG1LMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL9201393 | 0.80 | KDM4E (0.61) | LMNAHPGDKMT2ASMN1; SMN2HTT | |
| SCHEMBL4936220 | 0.79 | RAB9A (0.63) | OGG1LMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL11869994 | 0.79 | NOTUM (0.67) | OGG1LMNAKMT2ASMN1; SMN2HTT | |
| SCHEMBL11874801 | 0.79 | HSD17B10 (0.71) | OGG1LMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16835743 | 0.79 | HPGD (0.63) | OGG1LMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL3241147 | 0.78 | PKM (0.64) | LMNAHPGDKMT2ASMN1; SMN2HTT | |
| SCHEMBL29125701 | 0.78 | HSD17B10 (0.61) | OGG1SMN1; SMN2HTTALDH1A1KDM4E | |
| SCHEMBL15426820 | 0.77 | OGG1 (0.69) | OGG1LMNAHPGDKMT2AHTT | |
| SCHEMBL5009269 | 0.77 | GRM4 (0.55) | LMNAHPGDKMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | INOXIA LIFESCIENCES GMBH (AT) | 2013-03-14 | — | — | US | claimed |
| EP-2528595-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011091461-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) | 2011-08-04 | — | — | WO | claimed |
| EP-2965755-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2016-01-13 | — | — | EP | disclosed |
| EP-2965755-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2016-01-13 | — | — | EP | disclosed |
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | INOXIA LIFESCIENCES GMBH (AT) | 2013-03-14 | — | — | US | disclosed |
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | INOXIA LIFESCIENCES GMBH (AT) | 2013-03-14 | — | — | US | disclosed |
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | INOXIA LIFESCIENCES GMBH (AT) | 2013-03-14 | — | — | US | disclosed |
| EP-2528595-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011091461-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011091461-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) | 2011-08-04 | — | — | WO | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | SLC10A1, CYP27A1, OAT | OGG1 2188/4885LMNA 1432/4885HPGD 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.